DWP 212525
Alternative Names: DWP212525Latest Information Update: 20 Dec 2024
At a glance
- Originator Daewoong Pharmaceutical
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Preclinical COVID 2019 infections; Inflammatory bowel diseases
- No development reported Pemphigus vulgaris; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 20 Dec 2024 Preclinical trials in Autoimmune disorders in South Korea (Parenteral)
- 10 Dec 2024 Phase-I clinical trials in Autoimmune disorders (In adults, In volunteers) in South Korea (Parenteral) (NCT06736587)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Pemphigus-vulgaris in South Korea